Large market need Delpor’s yearlong sustained-release platform targets adherence challenges in CNS/Psychiatric conditions and chronic pain, presenting a large addressable market for schizophrenia, opioid use disorder, fibromyalgia, and other autoimmune diseases where adherence improves outcomes.

Clinical validation Phase II data for DLP-114 and the successful safety, efficacy, and pharmacokinetic profiles bolster credibility with KOLs and payers, supporting conversations around reimbursement pathways and off-label expansion opportunities across related therapies.

Payer and physician interest Positive market research from over 200 high-prescribing physicians and several US/EU payers indicates readiness among clinicians and payers to consider once-yearly or multi-month delivery options, enabling target-led outreach and pilot programs.

Strategic partnerships With a clinical-stage profile and a clear platform for long-acting delivery, there are opportunities to pursue collaborations with larger biopharma or specialty pharma players focusing on CNS, autoimmune, and pain indications to accelerate development and commercialization.

Funding and momentum Private funding and past NIH/NIMH grant support demonstrate external validation and potential for grants or co-development funding to de-risk late-stage development and expand into additional therapeutic areas.